Safety and Efficacy of Dexamethasone Intravitreal Implant in Korea
Phase of Trial: Phase IV
Latest Information Update: 03 Feb 2016
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary)
- Indications Branch retinal vein occlusion; Central retinal vein occlusion
- Focus Adverse reactions
- Sponsors Allergan
- 12 Jan 2016 Primary end point "Best Corrected Visual Acuity" is now removed so trial focus changed from TU + AR to AR. Also treatment for non-infectious uveitis affecting the posterior segment of the eye is now added so change in inclusion criteria and treatment according to ClinicalTrials.gov record.
- 22 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.
- 30 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.